Physician profile
Austin Malcom
NPI 1205311131
$6,377.39
in general payments reported to CMS, 2019-2025
20 companies · $2,840 in 2025
The $2,840 reported for 2025 was more than what 98% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.66 · 2022: $15.63 · 2023: $1,070 · 2024: $2,380 · 2025: $2,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,861 · Food and Beverage: $2,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,861.26 |
| Food and Beverage | $2,428.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $2,205.37 | 2025 | |
| Arthrex, INC. | $1,008.70 | 2024 | |
| Boston Scientific Corporation | $954.95 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| United Orthopedics LLC | $929.14 | 2023-2024 | |
| Intrinsic Therapeutics | $792.76 | 2024-2025 | Barricaid Acd (Annular Closure Device) |
| Radius Health, INC. | $86.21 | 2023-2025 | Tymlos |
| Depuy Synthes Sales INC. | $71.66 | 2021 | |
| Medtronic, INC. | $49.29 | 2024 | Unid_pass |
| Spine Wave, INC. | $37.20 | 2023 | Velocity Expandable Interbody System |
| Medical Device Business Services, INC. | $33.74 | 2024 | Teligen, Vivigen Mis Delivery System, Symphony |
| Stryker Corporation | $33.06 | 2023 | Avs Navigator |
| Vertex Pharmaceuticals Incorporated | $32.13 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $23.26 | 2025 | Airsupra |
| Abbott Laboratories | $21.21 | 2025 | Eterna |
| Azurity Pharmaceuticals, INC. | $20.61 | 2023 | Gliadel |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.09 | 2025 | Trelegy Ellipta |
| Pfizer INC. | $16.38 | 2025 | |
| Neurocrine Biosciences, INC. | $15.63 | 2022 | |
| Nevro Corp. | $15.36 | 2024 | Senza |
| Smith+Nephew, INC. | $13.64 | 2025 | Renasys Touch, Pico 14 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Malcom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.